Edition:
United States

Livzon Pharmaceutical Group Inc (000513.SZ)

000513.SZ on Shenzhen Stock Exchange

49.38CNY
26 Jul 2016
Change (% chg)

-- (--)
Prev Close
¥49.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,617,321
52-wk High
¥59.70
52-wk Low
¥35.42

000513.SZ

Chart for 000513.SZ

About

LIVZON PHARMACEUTICAL GROUP INC. is a China-based company principally engaged in research, development, production and distribution of pharmaceutical products. The Company primarily offers western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. The Company’s... (more)

Overall

Beta: 0.73
Market Cap(Mil.): ¥17,166.40
Shares Outstanding(Mil.): 396.63
Dividend: 0.50
Yield (%): 1.02

Financials

  000513.SZ Industry Sector
P/E (TTM): 28.90 36.91 37.71
EPS (TTM): 1.69 -- --
ROI: 15.17 15.22 14.43
ROE: 15.42 16.27 15.61

BRIEF-Livzon Pharmaceutical sees H1 net profit up 17-25 pct

* Says it expects H1 net profit to rise 17-25 percent y/y to 398.8-426.1 million yuan ($59.52-$63.72 million)

Jul 14 2016

BRIEF-Livzon Pharma gets regulatory approval for A-share private placement

* Says it gets securities regulator's approval to issue A-share in private placement

May 18 2016

BRIEF-Regulator to resume Livzon Pharma's private placement application

* Says securities regulator to resume review of its share private placement application

May 10 2016

BRIEF-Livzon Pharma's Q1 net profit up 26.0 pct

* Says Q1 net profit up 26.0 percent y/y at 230.1 million yuan ($35.51 million)

Apr 21 2016

BRIEF-Livzon Pharma's 2015 net profit up 20.7 pct

* Says 2015 net profit up 20.7 percent y/y at 622.6 million yuan ($95.62 million)

Mar 24 2016

BRIEF-Regulator to halt review of Livzon Pharma's private placement application

* sAYS securities regulator to halt review of its share private placement application

Mar 22 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.